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Abstract
The Nephrotic Syndrome Study Network (NEPTUNE) is a North American multi-center 
collaborative consortium established to develop a translational research infrastructure for 
Nephrotic Syndrome. This includes a longitudinal observational cohort study, a pilot and ancillary 
studies program, a training program, and a patient contact registry. NEPTUNE will enroll 450 
adults and children with minimal change disease, focal segmental glomerulosclerosis and 
membranous nephropathy for detailed clinical, histopathologic, and molecular phenotyping at the 
time of clinically-indicated renal biopsy. Initial visits will include an extensive clinical history, 
physical examination, collection of urine, blood and renal tissue samples, and assessments of 
quality of life and patient-reported outcomes. Follow-up history, physical measures, urine and 
blood samples, and questionnaires will be obtained every 4 months in the first year and bi-
annually, thereafter. Molecular profiles and gene expression data will be linked to phenotypic, 
genetic, and digitalized histologic data for comprehensive analyses using systems biology 
approaches. Analytical strategies were designed to transform descriptive information to 
mechanistic disease classification for Nephrotic Syndrome and to identify clinical, histological, 
and genomic disease predictors. Thus, understanding the complexity of the disease pathogenesis 
will guide further investigation for targeted therapeutic strategies.
Introduction
Primary non-inflammatory glomerular diseases that include minimal change disease (MCD), 
focal and segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN) are 
rare diseases that cause serious morbidity and high mortality accounting for approximately 
15% of prevalent ESRD cases (2008) at an annual cost in the USA of more than $3 
billion.1, 2 Our limited knowledge of underlying glomerular disease mechanisms is a major 
barrier to successful therapeutic intervention. To date, this void has not been overcome by 
surrogate clinical and histopathology-based classification methods, which are of limited 
value in reliably predicting disease natural history or responsiveness to therapy. Hence, there 
is a need for basic and translational investigation to identify underlying disease mechanisms, 
specific biomarkers, and therapeutic targets for further testing in clinical trials.
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Integration of large-scale multi-dimensional molecular and clinical data sets obtained from a 
well-characterized patient population could enhance our ability to understand the spectrum 
of molecular disease entities that present as a common histological phenotype, elucidate 
pathogenesis, and expedite scientific innovation toward safe and effective treatments for 
glomerular diseases3.
To facilitate studies of this type, the Nephrotic Syndrome Study Network (NEPTUNE), 
supported by the National Institutes of Diabetes and Digestive and Kidney Disease 
(NIDDK), and the Office for Rare Diseases Research (ORDR) at the National Institutes of 
Health (NIH), and The NephCure and Halpin Foundations, was designed to conduct multi-
disciplinary innovative research to address the “translational gap,” which is a barrier to 
successful management of adults and children with FSGS, MCD and MN.
The overall objectives of the NEPTUNE network (Table 1) are incorporated into the 
NEPTUNE observational cohort study that is designed to address the following general and 
disease-specific hypotheses:
1. After accounting for types, duration, and frequency of immunomodulating therapy, 
the probability of remission of FSGS, MCD and MN, defined as change in urinary 
protein excretion and/or renal function, will be predicted by baseline demographics, 
clinical, genetic, and histopathological characteristics at the time of presentation.
2. Genome-wide molecular profiles obtained from renal biopsy tissue at the time of 
diagnosis of FSGS, MCD and MN will independently predict the proportion of 
subjects entering remission.
3. Individual genetic causes of FSGS and MCD activate specific transcriptional 
pathways in renal tissue and the molecular characterization of these transcriptional 
pathways will identify novel therapeutic targets yielding more complete and 
sustained disease remission.
4. The use of non-immunomodulating therapy (including anti-hypertensive, lipid-
lowering, and antithrombotic agents and dietary manipulation) will have an 
independent effect on the probability of remission of nephrotic syndrome.
5. The composite rates of major medical complications (vascular thrombosis, 
complications of the kidney biopsy procedure, infection, and death) will vary 
according to the baseline characteristics and types of treatment in patients.
6. Nephrotic syndrome, its treatment and clinical outcomes, will have a varied 
measurable effect on quality of life of patients.
Results
Overview of Study Design and Organization
The NEPTUNE study is a prospective observational study that will enroll 450 children and 
adults with FSGS, MCD and MN at the time of first clinically-indicated renal biopsy for 
diagnosis of proteinuria. Enrollment from 18 clinical centers in the U.S. and Canada (Table 
2) will occur over 30 months with a minimum follow-up of 30 months. The two primary 
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study outcomes are change in urinary protein excretion and change in renal function as 
indicated in Table 3. Secondary study outcomes are quality of life assessment, development 
of new-onset diabetes, malignancies, infections, thromboembolic events, hospitalization, 
acute kidney injury, and death.
The NEPTUNE consortium infrastructure consists of a Steering Committee, a Central 
Digitalized Histopathological Archive at the NIH, a Central Biorepository, Biochemical 
Laboratory and Data Analysis and Coordinating Center (DACC) at the University of 
Michigan, an Observational Study Monitoring Board at the NIDDK, and an external 
Scientific Advisory Board.
The overall design of the NEPTUNE cohort study is depicted in Figure 1 and described in 
detail below, NEPTUNE is registered at clinicaltrials.gov under NCT01209000.
NEPTUNE Cohort Participants
The NEPTUNE study will enroll a diverse population reflective of the disease burden in 
North America. Eligible candidates for the NEPTUNE study are individuals of any age 
scheduled for a clinically-indicated renal biopsy with proteinuria ≥ 500 mg/day estimated 
from a 24-hour or spot (protein to creatinine ratio) urine collection. Patients with sub-
nephrotic proteinuria are included to capture the broad spectrum of clinical presentations4, 5. 
Exclusion criteria include patients with clinical, serological, or histological evidence of other 
renal diseases (e.g. diabetic nephropathy, systemic lupus erythematosus, etc), prior solid 
organ transplant, life expectancy < 6 months, and those who are unwilling or unable to 
consent. Cohort assignment is based on detailed renal histopathological analysis. 
Participants whose histopathology is not determined to be consistent with FSGS, MCD and 
MN are assigned to an “Other Glomerulopathies” cohort and retained in the study to serve as 
a comparison group and for future studies addressing these histopathologically-distinct 
entities. Eligible candidates over age 18 are enrolled after providing written, informed 
consent.
NEPTUNE Pediatric Population
Children are an important population affected by nephrotic syndrome (NS) and are enrolled 
in the NEPTUNE study at many clinical centers as indicated in Table 2. The NEPTUNE 
study will enroll eligible children after parental written consent (and child assent when 
appropriate) prior to the diagnostic renal biopsy. Information on medications prescribed for 
NS prior to enrollment will be collected in all participants including children who may have 
a longer exposure to pre-biopsy therapies consistent with standard pediatric nephrotic 
syndrome management6. Additional funding to enroll children from initial nephrotic 
syndrome presentation is currently being pursued.
Study Enrollment and Follow-Up Visits
The enrollment process includes a screening visit to assess eligibility and willingness to 
participate, a baseline visit for collection of clinical and demographic information, and a 
renal biopsy visit to obtain renal tissue samples. Renal biopsy material will be used to 
confirm assignment into the specific study cohort and for research purposes. The baseline 
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visit includes collection of a detailed medical history, sociodemographic information, 
physical measures, and blood and urine samples (see https://rarediseasesnetwork.epi.usf.edu/
NEPTUNE/professional/studynetwork.htm# for details). In addition to age-appropriate 
questionnaires to assess quality of life, self-reported health will be evaluated using the 
Patient Reported Outcomes Measurement Information System (PROMIS, 
www.nihpromis.org). After enrollment, NEPTUNE participants are evaluated at 4-month 
intervals during the first year and every 6 months thereafter with similar data collection as 
performed in the baseline visit.
NEPTUNE Pathology Digital Imaging and Scoring System
Pathology material including glass slides, immunofluorescence images, and electron-
micrographs, will be scanned into high resolution digital images and stored in the 
NEPTUNE pathology database along with copies of the local pathology reports. This 
database can be accessed remotely by the NEPTUNE Histopathology committee for review, 
scoring, and cohort assignment by disease classification.
The NEPTUNE Histopathology Committee has developed a novel strategy for scoring renal 
biopsies designed to standardize morphologic analysis78. The pathology protocol is designed 
to provide 1) multi-level annotation of glomeruli for multi-dimensional reconstruction to 
allow simultaneous review and scoring of the same glomerulus on each digital slide, and 2) 
identification and scoring of specific pre-defined morphologic “descriptors”. This approach 
for kidney tissue analysis has the potential to redefine histopathologic classification and link 
these novel criteria to clinical and molecular phenotypes. In addition, the NEPTUNE 
pathology database will serve as a major resource available to investigators for future pilot 
and ancillary studies.
Overview of Applied Systems Biology Analysis Strategy
Systems biology is an emerging scientific approach that aims to address the ‘pluralism of 
cause and effects in biological networks’9 that defines the steady state and its disturbances in 
health and disease10111213, 14. The NEPTUNE study aims to integrate comprehensive 
clinical and pathologic phenotypes with extensive analysis of the molecular regulatory 
networks active in glomerular diseases. As depicted in figure 2, NEPTUNE will 
prospectively procure human samples for analyses focused on genome-wide profiling of 
genetic variation, epigenetic markers and transcriptomic, proteomic, and metabolomic 
profiles. Emerging systems biology approaches will be used to define associations between 
these multi-phasic and inter-related genome scale profiles and the detailed clinical and 
structural phenotypes.
The NEPTUNE study will establish a core molecular data set containing genetic profiles and 
renal tissue, compartment-specific, genome wide mRNA expression data to facilitate multi- 
and trans-disciplinary research exploration along the genotype – phenotype 
continuum10111213.The NEPTUNE core data sets will provide a foundation to link 
mechanistic information with clinical disease presentation, and link molecular information 
from model systems with human nephrotic syndrome data sets. Patient subgroups with 
activation of specific molecular mechanisms can be used to assess the efficacy of novel 
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therapeutics in a highly targeted manner. Defining patients by the underlying disease 
mechanism will reduce the heterogeneity inherent to the current histology-based glomerular 
disease classification and, as a result, will focus the analysis and interpretation of clinical 
trials.
The core and ancillary data generated in NEPTUNE can be a significant resource to the 
renal research community. NEPTUNE will utilize Nephromine (www.Nephromine.org), a 
renal-specific systems biology search engine, to enable large-scale data analysis by 
nephrology investigators with and without systems biology expertise.
Statistical Considerations
The research aims will be explored separately in FSGS, MCD cohort and MN cohort. The 
primary objective of the statistical analysis plan is to build a predictive model that utilizes 
multiple sources of data, including molecular biomarkers and auxiliary predictors (e.g. race/
ethnicity, edema), to classify patients according to the proteinuria outcome (remission) as 
the primary endpoint. Secondary study endpoints include longitudinal measures of renal 
function. The primary analysis plan involves deriving a prediction model to rigorously 
evaluate and identify potential predictors for study endpoints. Subsequently, the overall 
prediction model will be used to assess relative risk and association via odds ratios for 
targeted sub-group analysis. In analysis of data from the network, random-effects models 
will be used to account for potential heterogeneity and unstructured interventions across and 
within the clinical centers. Also, the analysis is tailored to handle dropouts, incomplete 
longitudinal data, and other types of missing data15. For further details on statistical 
methodology, see Supplement.
For biomarker discovery and validation, the sample will be split into the training and the 
validation sets at the ratio of 16, 17. With regard to the primary endpoint, selection of 
biomarkers (e.g. gene expression levels or serum or urine proteomic markers) will proceed 
in two steps: first, univariate variable screening will identify a small pool of promising 
biomarkers and, subsequently, joint screening to narrow identified candidate biomarkers to 
those with the optimal predictive power. Using selected biomarkers, a prediction model will 
be developed that is further validated via the test cohort by the criteria of ROC curves and 
net reclassification index18, 19. In the analysis of secondary endpoints, similar strategies will 
be applied to build prediction models to classify longitudinal trajectories (e.g. estimated 
GFR).
Sample Size Consideration
The NEPTUNE study will have adequate power to identify important molecular biomarkers 
predicting the primary endpoints. Power calculations were based on the probability of 
correct classification (PCC)20. The expected probability of PCC is a weighted average of 
sensitivity (probability o f remission) and specificity (probability of non-remission). An 
estimate 20,000 genes (probes) and 75 auxiliary predictors will be screened to identify true 
gene expression markers and true auxiliary predictor for the defined endpoints (Table 4). 
The PCCs are 0.874, 0.942 and 0.966 for the sample sizes of 100, 150 and 200, respectively, 
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based on the identification of 50 true gene expression markers and 10 true auxillary markers. 
The NEPTUNE study enrollment goal is to enroll 450 subjects.
NEPTUNE Training, Ancillary Study and Outreach Program
In the spirit of accelerating NS research, NEPTUNE has organized a pilot and ancillary 
studies program to facilitate high-quality investigation within the research community 
utilizing the resources provided by the NEPTUNE infrastructure. The ancillary studies 
mechanism is open to investigators regardless of institutional affiliation. Details on the 
available data, specimens and process required to gain access to these resources are provided 
at https://rarediseasesnetwork.epi.usf.edu/NEPTUNE/professional/studynetwork.htm#. 
Further, NEPTUNE supports a training program for post-doctoral fellows and junior faculty 
to promote career development in clinical and translational research in glomerular disease 
(https://rarediseasesnetwork.epi.usf.edu/NEPTUNE/professional/fellowship/). Lastly, 
NEPTUNE has organized a contact registry within the Rare Diseases Clinical Research 
Network (www.neptune-study.org) for patients with NS. This registry contains self-reported 
information, including diagnostic, demographic, and contact information that can be used 
for patient education and to facilitate enrollment of patients into clinical trials and other 
research studies. At the time of this publication, over 1300 patients are actively enrolled in 
the NEPTUNE contact registry and a substantial number of registrants have provided 
consent to be directly approached for participation in clinical studies.
Discussion
Primary NS is a debilitating clinical entity affecting individuals of all ages and associated 
with end-stage renal disease and premature death. We remain limited in our ability to 
effectively treat the specific diseases presenting as NS due to our lack of understanding of 
disease mechanisms and lack of predictors to identify clinical course and therapeutic 
responsiveness. The NEPTUNE cohort study is designed to address these gaps in knowledge 
in prominent NS disorders, FSGS, MCD and MN, by developing a platform for 
comprehensive longitudinal assessment of patients with incipient disease. This study 
represents strong commitment to bring together expertise from a broad range of disciplines 
focused on large-scale integration of clinical, histopathologic and molecular data. This state-
of-the-art approach to identify pathogenic mechanisms and novel biomarkers has the 
greatest potential to advance medical management of these complex diseases.
Epidemiologic data demonstrates an increased incidence of primary NS due to FSGS over 
several decades in adults and children21. In young children, MCD remains the predominant 
etiology of primary NS. However, 10–15% of primary NS is caused by MCD in adults. 
FSGS and MCD are often considered related entities due to their similarities in clinical 
presentation, renal pathologic features as well as common genetic polymorphisms22, 23, but 
a systematic comparative analysis in sporadic patients is lacking. Although the clinical 
course can be highly variable, patients with FSGS are more likely resistant to glucocorticoid 
therapy and have greater risks for kidney failure. A variety of monogenetic mutations (both 
dominant and recessive patterns) with distinct functional consequences have been identified 
that present with indistinguishable FSGS-type lesions signifying heterogeneity in disease 
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pathogenesis22, 24–29. Therefore, it is evident that the current classification and diagnostic 
tools are insufficient in guiding therapy. The paucity of conclusive clinical interventional 
studies for glomerular disease in general underscores the need to establish predictive 
biomarkers and therapeutic targets for future trials in molecularly-defined NS cohorts30.
Recent discovery of genetic risk loci in linkage disequilibrium with APOL1 and MYH931–33 
among people of African descent with FSGS (and potentially other kidney disease) is a 
major step toward understanding racial/ethnic disparities in kidney disease. Recruitment of a 
diverse study population from sites located across North America provides opportunities to 
explore, in a longitudinal fashion, the clinical manifestations and therapeutic implications of 
these and other genetic variants.
MN is a common cause of primary NS in adults34, 35 and has a highly variable course from 
spontaneous remission to progression to end-stage renal disease. As with FSGS and MCD, 
renal tissue classification is descriptive and not associated with clinical course. The clinical 
course is highly variable and difficult to predict at presentation often leading to prolonged 
observation of patients by clinicians to determine prognosis and guide therapy36, 3738. 
Recent evidence suggests that circulating phospholipase A2 receptor autoantibodies may be 
an immunologic marker for the majority of cases of primary MN39, 40. A major emphasis for 
the MN cohort in NEPTUNE is to understand the value of these new biomarkers in 
predicting disease progression and response to treatment.
In line with the major goals of the consortium, the NEPTUNE pathology protocol for 
scoring renal biopsies has the potential to re-define morphologic descriptors utilizing 
innovative digital methodology and serve as an extensive resource for future ancillary 
studies. This approach to renal biopsy analysis has potential applicability for risk 
stratification, disease classification and clinical trial design.
There is rapid expansion of information about monogenetic diseases and genetic loci 
associated with NS. However, discovering the functional links that bridge the gap from 
genetic risk to disease phenotype is one of the main challenges ahead. The NEPTUNE 
cohort study has been designed to bridge this genotype-phenotype gap using the integrated 
approaches of systems biology. These emerging innovative strategies will be the first steps 
towards identifying and testing rational interventions in primary NS. Overall, the NEPTUNE 
study and its complementary programs provide unparalleled opportunities to make 
fundamental observations using state-of-the-art research methodology, foster collaborative 
scientific activity, and facilitate research career development to stimulate progress in the 
management of glomerular diseases.
Methods
See supplement for a more detailed definition of statistical methodology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. NEPTUNE Cohort Study Design
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Figure 2. Overview of Multilevel Data Integration in NEPTUNE
“The integrative analytical approach in NEPTUNE relies on obtaining comprehensive 
molecular and clinical information from each subject. For molecular analysis, the initial step 
is to generate large-scale datasets of genome-wide genetic variation and targeted gene 
sequencing, compartment specific gene expression data on renal biopsy tissue, leukocytes 
and urine, and proteomic/metabolomic data from both urine and blood samples. Each 
molecular dataset will be interrogated alone and in relationship with the others in order to 
understand multidimensional molecular interactions. In addition, the molecular data will be 
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analyzed with the comprehensive clinical information to determine associations between 
molecular events and clinical outcomes. The overall goal is to develop a framework for 
studies to define the molecular heterogeneity of NS for disease stratification, biomarker 
identification and molecular target definition. (Figure modified from Keller et al10).”
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Table 1
Objectives of the Nephrotic Syndrome Study Network (NEPTUNE)
Objectives of the Nephrotic Syndrome Study Network
Establish a collaborative, integrated, cost-effective investigational infrastructure to conduct clinical and translational research in FSGS, MCD, 
and MN
Perform a longitudinal observational cohort study on patients with incipient biopsy proven NS
Establish Pilot and Ancillary Projects Programs using the unique resources, clinical data, or specimens collected by NEPTUNE
Establish a Training Program for post-doctoral/junior faculty trainees to prepare for clinical and translational research in glomerular disease
Collaborate with the ORDR Data Management and Coordinating Center and the NephCure Foundation to establish a web-based exchange 
platform for lay people, physicians, and scientists.
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Table 2
Nephrotic Syndrome Study Network Clinical Centers
NEPTUNE Clinical Centers* Recruitment Population
Case Western Medical Center, Cleveland, OH Adult and Pediatric
Cohen’s Children’s Medical Center, Manhasset, NY Pediatric
Columbia University, New York, NY Adult
Emory University, Atlanta, GA Pediatric
Harbor Biomedical Research Institute, Torrance, CA Adult
Johns Hopkins Medical Center, Baltimore, MD Pediatric
Montefiore Medical Center, Bronx, NY Adult and Pediatric
The Mayo Clinic, Rochester, MN Adult and Pediatric
National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD Adult
New York University School of Medicine, New York, NY Adult and Pediatric
Temple University Health Systems, Philadelphia, PA Adult
University Health Network, Toronto, Canada Adult
University of Michigan Health Systems, Ann Arbor, MI Adult and Pediatric
University of Miami Medical Center, Miami, FL Adult and Pediatric
University of North Carolina, Chapel Hill, NC Adult and Pediatric
University of Pennsylvania, Philadelphia, PA Adult and Pediatric
University of Southern California Children’s Hospital, Los Angeles, CA Pediatric
University of Washington, Seattle, WA Adult and Pediatric
*
For full list of sites enrolling NEPTUNE participants, see Appendix
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Table 3
NEPTUNE Primary Outcome Variables and Definitions
Rate of Change in Urinary Protein Excretion from Baseline (UP:C ratio) Rate of Change in Renal Function 
from
Baseline
Definitions Standard Cohort Study Cohort Study
Reduction in UP:C ratio of ≤0.3






25 ml/min/1.73m2 reduction in 
eGFR*
Reduction in UP:C ratio > 50% and final >3.5
Reduction in UP:C ratio < 50% (includes increases < 
50%)





No Response 50% decline in eGFR from baseline
New development of UP:C ratio >3.5 after complete or 
partial remission
Relapse Relapse ESRD (initiation of dialysis, kidney 
transplantation or eGFR ≤ 10 
ml/min/1.73m2
“Abbreviations: UP:C = urine protein: creatinine (g/g); eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease”
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